Clinical Trials Logo

Recurrent Pleural Malignant Mesothelioma clinical trials

View clinical trials related to Recurrent Pleural Malignant Mesothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02568449 Recruiting - Clinical trials for Stage IV Pleural Mesothelioma

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02408016 Active, not recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Start date: May 20, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma. Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell from patients, called T cells, and modifies their genes in the laboratory so that they are programmed to find cells with WT1 and kill them. The T cells are then given back to the patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may help the body build an immune response to kill tumor cells.

NCT ID: NCT02399371 Recruiting - Clinical trials for Pleural Malignant Mesothelioma

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.